Version of Record online: 17 JAN 2013
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 57, Issue 5, pages 1752–1762, May 2013
How to Cite
Everson, G. T., Terrault, N. A., Lok, A. S., Rodrigo, D. R., Brown, R. S., Saab, S., Shiffman, M. L., Al-Osaimi, A. M.S., Kulik, L. M., Gillespie, B. W., Everhart, J. E. and and the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (2013), A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology, 57: 1752–1762. doi: 10.1002/hep.25976
Potential conflict of interest: Dr. Everson advises, consults for, and received grants from Merck and Schering-Plough. Dr. Terrault consults for, and received grants from Roche and Genentech. Dr. Lok consults for and received grants from Schering-Plough, Merck, Roche, and Genentech. Dr. Brown consults for Merck. Dr. Saab owns stock in, consults for, advises, and is in the speakers' bureau of Bristol-Myers Squibb. He consults for, advises, and is on the speakers' bureau of Genentech and Merck. Dr. Al-Osaimi consults for, advises, is on the speakers' bureau of, and received grants from Merck and Vertex. He is on the speakers' bureau of and received grants from Idenix, Novartis, and Gilead. He also consults for Amgen and received grants from Genentech, Valeant, Intermune, Pharmasset, HemoLife Medical, Genzyme, Ortho Biotech, GalxoSMithKline, Sanofi-Aventis, Bayer Healthcare, Hyperion, Bristol-Myers Squibb, Vital, and Octapharma. Dr. Shiffman advises and received grants from Achillion, Boehringer-Ingelheim, Globeimmune, Inhibitex, Novartis, Vertex, and Zymogenetics. He consults for Biolex, Human Genome Sciences, Romark. He advises Pfizer and Janssen. He received grants from Idenix. He advises, is on the speakers' bureau of, and received grants from Schering-Plough, Gilead, and Bristol-Myers Squibb. He consults for, advises, and received grants from Conatus. He consults for, advises, is on the speakers bureau of, and received grants from Roche and Anandys. He is on the speakers' bureau of and advises Bayer.
The results of this study were presented, in part, at the 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 30-November 1, 2009.
The study is registered in ClinicalTrials.gov (no. NCT00135798).
This is publication 18 of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study.
- Issue online: 22 APR 2013
- Version of Record online: 17 JAN 2013
- Accepted manuscript online: 23 JUL 2012 06:09AM EST
- Manuscript Accepted: 11 JUN 2012
- Manuscript Received: 8 MAR 2012
Additional Supporting Information may be found in the online version of this article.
|HEP_25976_sm_SuppFig1A.tif||265K||Supporting Information Figure 1A.|
|HEP_25976_sm_SuppFig1B.tif||250K||Supporting Information Figure 1B.|
|HEP_25976_sm_SuppTables.doc||58K||Supporting Information Tables|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.